Osteoporosis, Postmenopausal

Known as: Postmenopausal Bone Losses, Bone Losses, Perimenopausal, Osteoporoses, Post-Menopausal 
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after… (More)
National Institutes of Health

Related topics

Related topics

46 relations
10 ML Pamidronate Disodium 3 MG/ML Injection84 HR Estradiol 0.00156 MG/HR Transdermal System [Vivelle]84 HR Estradiol 0.00208 MG/HR Transdermal System [Alora]84 HR Estradiol 0.00208 MG/HR Transdermal System [Vivelle]
(More)

Broader (1)

Osteoporosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
An overview and management of osteoporosis.
Osteoporosis -related to various factors including menopause and aging- is the most common chronic metabolic bone disease, which… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
The development of bone-rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Review
2007
Review
2007
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures, which are often… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
BACKGROUND Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
BACKGROUND Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs… (More)
Is this relevant?
Review
2002
Review
2002
Treatment of postmenopausal osteoporosis
The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
BACKGROUND Once-daily injections of parathyroid hormone or its amino-terminal fragments increase bone formation and bone mass… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT…
CONTEXT Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Review
1991
Review
1991
The ovariectomized rat model of postmenopausal bone loss.
An animal model of postmenopausal bone loss can be defined as a living animal in which spontaneous or induced bone loss due to… (More)
Is this relevant?